Determination of 1-(2-chloroethyl)-3-(2,6-dioxo-3-piperidyl)-1-nitrosourea in plasma by negative chemical ionization mass spectrometry.

Abstract

A sensitive and specific method for the quantitative determination of a new antitumor agent, 1-(2-chloroethyl)-3-(2,6-dioxo-3-piperidyl)-1-nitrosourea, (PCNU) has been developed for the analysis of plasma. This assay involves extraction of the plasma sample, separation of the drug by thin-layer chromatography and mass spectrometric detection of the negative ions derived from the unchanged drug and its 2H4-labeled analog. Ion current profile peaks are obtained when drug samples are introduced into the heated source using a desorption chemical ionization probe. Detection limits are below 1.0 ng ml-1 of plasma. This method has been applied to determine the in vitro rate of decomposition of PCNU in plasma and the plasma clearance of this drug from a cancer patient.

• Authors: R G Smith, L K Cheung, L G Feun, T L Loo
• Journal: Biomedical mass spectrometry (Biomed Mass Spectrom) Vol. 10 Issue 7 Pg. 404-7 (Jul 1983) ISSN: 0306-042X [Print] England
• PMID: 6616018 (Publication Type: Journal Article, Research Support, U.S. Gov't, P.H.S.)

Chemical References

• Antineoplastic Agents
• Nitrosourea Compounds
• 1-(2-chloroethyl)-3-(2,6-dioxo-3-piperidinyl)-1-nitrosourea

Topics

• Antineoplastic Agents (blood)
• Chromatography, Thin Layer (methods)
• Humans
• Mass Spectrometry (methods)
• Nitrosourea Compounds (blood)